University of Colorado Hospital
Denver, Colorado, 80237, United States
Location status: Recruiting
NCT Number: NCT04611022
The educational intervention to be delivered by the PN(Patient Navigator) consists of "toolkit education materials" developed by the National Cancer Institute (NCI) and a small media intervention (i.e., video) that our research team has developed. The NCI-produced toolkit education materials consist of Power Point presentations, flyers, and posters that contain information about HPV(Human Papilloma Virus), HPV-related cancers, and the importance of the HPV vaccine series for adolescents (9-17 years old) and young adults (18-26 year old) who are eligible for the vaccine.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Denver, Colorado, 80237, United States
Location status: Recruiting
The investigator will use a one-group post-test design to assess the effects of the intervention on the primary outcomes. The educational intervention will be delivered to 400 participants by a trained CHE who will deliver the educational materials to eligible DHHA patients. The CHE will administer the post-education survey at baseline to participants. Additionally, we will use a one-group post-test design to assess the impact of the intervention on the secondary outcomes. At the patient-level, we will track participants that receive (a) 1st dose, 2nd dose, or 3rd dose of the HPV vaccine; and the number of referrals to care by recording the number of patients received (b) referrals to health insurance, discount, or no-cost HPV vaccine programs; or (c) to other services to facilitate HPV vaccine dose completion. To assess clinic-level impact, we will track each clinic's HPV vaccine rates for adolescents (9-17 years old) and young adults (18-26) and compare rates from before we start the intervention and then quarterly there after we have introduced the intervention to each respective Denver Health clinic.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The videos are 8-minute narrative films created using an entertainment-education (E-E) approach that embeds an educational narrative message into an entertainment format such as media. E-E narratives have demonstrated a significant effect (r = .12, p < .001) on health behavior change. Evidence-based small media interventions that Dr. Borrayo has produced include videos that are highly verbal, visual, and entertaining (e.g., acted fictional stories). The aims of the video will be to model uptake of the HPV vaccine, but also to reinforce self-efficacy, subjective norms, and behavioral intentions, all significant precursors to behavior change.
Time frame: Day 0/Baseline
Behavioral factors precede uptake of preventive vaccines. Measured by survey post watching HPV video.
Time frame: Day 0/Baseline
Collected by the study team. Variables known as associated with vaccine uptake
Time frame: 3 and 6 months post intervention
As determined by follow up phone calls. Number of vaccine doses are used to assess full protection (3 doses) or partial (<3 doses)
Time frame: 3, 6, 9 and 12 months post intervention
Interventions that can be delivered to impact patients & clinics are easier to implement. As determined by rates of HPV vaccine dose completion reported by clinics
Contact information is provided by the study sponsor or research team.
University of Colorado, Denver
Other
Intervention to Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine Series
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04645602
Human Papilloma Virus, Lung Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT03351855
Human Papilloma Virus
Shenzhen, Guangdong, China
View Trial DetailsNCT06414057
Human Papilloma Virus
Edinburgh, United Kingdom
View Trial DetailsNCT06747390
Carcinoma, Carcinoma, Squamous Cell
Philadelphia, Pennsylvania, United States
View Trial Details